Mecapegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-08-11 DOI:10.1002/hed.27897

Qifeng Jin, Yonghong Hua, Ting Jin, Lei Wang, Changjuan Tao, Shuang Huang, Weifeng Qin, Xiaozhong Chen

{"title":"Mecapegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study.","authors":"Qifeng Jin, Yonghong Hua, Ting Jin, Lei Wang, Changjuan Tao, Shuang Huang, Weifeng Qin, Xiaozhong Chen","doi":"10.1002/hed.27897","DOIUrl":null,"url":null,"abstract":"Background: Induction chemotherapy of docetaxel plus cisplatin (TP) is myelosuppressive, leading to severe neutropenia and febrile neutropenia (FN). Herein, we aimed to investigate the efficacy and safety of mecapegfilgrastim in the prevention of neutropenia in patients with locally advanced nasopharyngeal carcinoma who received the TP regimen.Methods: A total of 30 treatment-naive patients with locally advanced nasopharyngeal carcinoma were included in this study. Mecapegfilgrastim 6 mg was injected 24-48 h after the completion of induction chemotherapy with the TP regimen.Results: The incidence of grade ≥3 neutropenia during the three induction chemotherapy cycles was 6.7% (95% CI, 0.8%-22.1%). In the first cycle of chemotherapy, the incidence of grade ≥3 neutropenia was 3.3% (95% CI, 0.1%-17.2%). No FN or antibiotic usage was reported. All 30 patients completed the induction chemotherapy cycles.Conclusion: Mecapegfilgrastim effectively reduced the incidence of chemotherapy-induced neutropenia and FN in patients with locally advanced nasopharyngeal carcinoma.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.27897","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Induction chemotherapy of docetaxel plus cisplatin (TP) is myelosuppressive, leading to severe neutropenia and febrile neutropenia (FN). Herein, we aimed to investigate the efficacy and safety of mecapegfilgrastim in the prevention of neutropenia in patients with locally advanced nasopharyngeal carcinoma who received the TP regimen.

Methods: A total of 30 treatment-naive patients with locally advanced nasopharyngeal carcinoma were included in this study. Mecapegfilgrastim 6 mg was injected 24-48 h after the completion of induction chemotherapy with the TP regimen.

Results: The incidence of grade ≥3 neutropenia during the three induction chemotherapy cycles was 6.7% (95% CI, 0.8%-22.1%). In the first cycle of chemotherapy, the incidence of grade ≥3 neutropenia was 3.3% (95% CI, 0.1%-17.2%). No FN or antibiotic usage was reported. All 30 patients completed the induction chemotherapy cycles.

Conclusion: Mecapegfilgrastim effectively reduced the incidence of chemotherapy-induced neutropenia and FN in patients with locally advanced nasopharyngeal carcinoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

预防局部晚期鼻咽癌化疗引起的中性粒细胞减少症的美加非格司亭：一项前瞻性 II 期临床研究。

背景：多西他赛加顺铂（TP）的诱导化疗具有骨髓抑制作用，会导致严重的中性粒细胞减少症和发热性中性粒细胞减少症（FN）。在此，我们旨在研究麦卡非格司亭在预防接受TP方案的局部晚期鼻咽癌患者中性粒细胞减少症方面的有效性和安全性：本研究共纳入了30名未接受过治疗的局部晚期鼻咽癌患者。在TP方案诱导化疗结束后24-48小时注射美加非格司亭6毫克：结果：在三个诱导化疗周期中，≥3级中性粒细胞减少症的发生率为6.7%（95% CI，0.8%-22.1%）。在第一个化疗周期中，≥3级中性粒细胞减少症的发生率为3.3%（95% CI，0.1%-17.2%）。无 FN 或抗生素使用报告。所有30名患者均完成了诱导化疗周期：结论：美卡非格司亭能有效降低局部晚期鼻咽癌患者化疗引起的中性粒细胞减少症和FN的发生率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊